Presentation AHA 2024 Catheter Ablation or Antiarrhythmic Drug Therapy for Ventricular Tachycardia in Ischemic Cardiomyopathy: The VANISH2 Trial Presenter: John Sapp November 16, 2024
Presentation AHA 2016 The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I) Presenter: Michael Gibson November 15, 2016